These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 5165600

  • 41. Intravesical chemoprophylaxis of superficial transitional cell carcinoma of the bladder. When should the drug be given?
    Bouffioux C.
    Prog Clin Biol Res; 1985; 185B():47-55. PubMed ID: 4034591
    [No Abstract] [Full Text] [Related]

  • 42. [Intravesical BCG therapy for superficial bladder cancer].
    Segawa N, Iwamoto Y, Azuma H, Yamamoto K, Ueda H, Katsuoka Y.
    Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
    [Abstract] [Full Text] [Related]

  • 43. Intravesical thiotepa in prevention of recurrence of bladder tumour.
    Ghosal SK, Sen DK.
    J Indian Med Assoc; 1980 Nov 01; 75(9):173-4. PubMed ID: 6785360
    [No Abstract] [Full Text] [Related]

  • 44. Proceedings: Adjuvant intravesical thiotepa and bladder tumour recurrence.
    Boyd PJ, Burnand KG.
    Br J Surg; 1975 Feb 01; 62(2):162. PubMed ID: 803851
    [No Abstract] [Full Text] [Related]

  • 45. Re: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.
    Stewart AB, Mostafid H.
    J Urol; 2005 Apr 01; 173(4):1433; author reply 1433. PubMed ID: 15758827
    [No Abstract] [Full Text] [Related]

  • 46. BCG versus cytotoxic chemotherapy in the treatment of superficial bladder tumors.
    Boccon-Gibod L.
    Prog Clin Biol Res; 1992 Apr 01; 378():55-7. PubMed ID: 1301586
    [No Abstract] [Full Text] [Related]

  • 47. Recurrence prophylaxis of bladder cancer.
    Pavone-Macaluso M.
    Ann Chir Gynaecol; 1984 Apr 01; 73(4):243. PubMed ID: 6508205
    [No Abstract] [Full Text] [Related]

  • 48. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.
    van der Meijden AP.
    Prog Clin Biol Res; 1992 Apr 01; 378():95-101. PubMed ID: 1301591
    [No Abstract] [Full Text] [Related]

  • 49. [Prevention of the recurrence of superficial bladder cancer].
    Flamm J, Grof F.
    Z Urol Nephrol; 1984 Mar 01; 77(3):129-36. PubMed ID: 6720112
    [Abstract] [Full Text] [Related]

  • 50. [Polyarthritis as a rare complication in BCG immunoprophylaxis of urinary bladder cancer].
    Varentsov GI, Zakhmatov IuM, Kornev AI, Otvetchikov IN.
    Urologiia; 1999 Mar 01; (5):29-30. PubMed ID: 11150151
    [Abstract] [Full Text] [Related]

  • 51. Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done?
    Soloway MS, Arianayagam M.
    Urology; 2010 Oct 01; 76(4):794-6. PubMed ID: 20932403
    [No Abstract] [Full Text] [Related]

  • 52. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
    Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, Filbeck T.
    Urology; 2007 Apr 01; 69(4):675-9. PubMed ID: 17445650
    [Abstract] [Full Text] [Related]

  • 53. [Trial chemotherapy in the treatment of bladder cancers].
    Le Duc A, Camey M.
    J Urol Nephrol (Paris); 1974 Apr 01; 80(7-8):684-8. PubMed ID: 4444069
    [No Abstract] [Full Text] [Related]

  • 54. [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].
    Hinotsu S, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, Machida T, Matsumura Y, Niijima T, Obata K, Ohashi Y, Ohe H, Shimazaki J, Tashiro K, Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin.
    Gan To Kagaku Ryoho; 2002 Jan 01; 29(1):73-80. PubMed ID: 11816482
    [Abstract] [Full Text] [Related]

  • 55. [The prevention of the recurrence of stage pTa bladder tumors using intravesical instillation of BCG].
    Wetzel O, Glemain P, Bouchot O, Guillonneau B, Baron M, Buzelin JM, Auvigne J.
    Prog Urol; 1993 Jan 01; 3(4):595-607. PubMed ID: 8401620
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. [Transurethral resection in large non-invasive tumors of the bladder].
    Sánchez de Badajoz E.
    Arch Esp Urol; 1985 Jan 01; 38(4):393-400. PubMed ID: 4073965
    [No Abstract] [Full Text] [Related]

  • 59. [Prognostic factors and risk of recurrence in a series of 385 patients with superficial bladder carcinoma treated with thiotepa, adriamycin or cisplatin].
    Llopis B, Sánchez A, Boronat F, Gallego J, Moreno B, Alonso M, Martínez R, Vera CD, Jiménez JF.
    Arch Esp Urol; 1987 Apr 01; 40(3):159-64. PubMed ID: 3113347
    [No Abstract] [Full Text] [Related]

  • 60. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M, McGarry R, Kupelnick B.
    Anticancer Res; 2001 Apr 01; 21(1B):765-9. PubMed ID: 11299841
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.